KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip, Pei Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, PALOMA-3 Investigators

J Clin Oncol 42(30) 3593-3605

PMID38857463
PMCIDPMC11469630
DOI10.1200/JCO.24.01001
发表日期2024-06-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已完成可用 Figure 的视觉复核,未识别到合格 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 10 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:非 KM 图;FIG 4.:非 KM 图;FIG A1.:研究设计图;另有 5 张未列出。
摘要

摘要

PURPOSE: Phase III studies of intravenous amivantamab demonstrated efficacy across epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). A subcutaneous formulation could improve tolerability and reduce administration time while maintaining efficacy. PATIENTS AND METHODS: Patients with EGFR-mutated advanced NSCLC who progressed after osimertinib and platinum-based chemotherapy were randomly assigned 1:1 to receive subcutaneous or intravenous amivantamab, both combined with lazertinib. Coprimary pharmacokinetic noninferiority end points were trough concentrations (Ctrough; on cycle-2-day-1 or cycle-4-day-1) and cycle-2 area under the curve (AUCD1-D15). Key secondary end points were objective response rate (ORR) and progression-free survival (PFS). Overall survival (OS) was a predefined exploratory end point. RESULTS: Overall, 418 patients underwent random assignment (subcutaneous group, n = 206; intravenous group, n = 212). Geometric mean ratios of Ctrough for subcutaneous to intravenous amivantamab were 1.15 (90% CI, 1.04 to 1.26) at cycle-2-day-1 and 1.42 (90% CI, 1.27 to 1.61) at cycle-4-day-1; the cycle-2 AUCD1-D15 was 1.03 (90% CI, 0.98 to 1.09). ORR was 30% in the subcutaneous and 33% in the intravenous group; median PFS was 6.1 and 4.3 months, respectively. OS was significantly longer in the subcutaneous versus intravenous group (hazard ratio for death, 0.62; 95% CI, 0.42 to 0.92; nominal P = .02). Fewer patients in the subcutaneous group experienced infusion-related reactions (IRRs; 13% v 66%) and venous thromboembolism (9% v 14%) versus the intravenous group. Median administration time for the first infusion was reduced to 4.8 minutes (range, 0-18) for subcutaneous amivantamab and to 5 hours (range, 0.2-9.9) for intravenous amivantamab. During cycle-1-day-1, 85% and 52% of patients in the subcutaneous and intravenous groups, respectively, considered treatment convenient; the end-of-treatment rates were 85% and 35%, respectively. CONCLUSION: Subcutaneous amivantamab-lazertinib demonstrated noninferiority to intravenous amivantamab-lazertinib, offering a consistent safety profile with reduced IRRs, increased convenience, and prolonged survival.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(10,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.CONSORT diagram of patient disposition. AE, adverse event.
非 KM Figure
FIG 2.(A) Objective response forest plot, (B) PFS, and (C) OS. The efficacy population included all patients who had undergone random assignment. (A) The shaded area indicates 95% CIs for the relative risk in all patients; the subgroup analyses were not part of the hypothesis testing and results are reported without adjustment for multiplicity. (B, C) The dashed lines indicate the median PFS and OS, respectively, in the two groups, and the tick marks indicate censoring of data. ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
非 KM Figure
FIG 3.IRRs and infusion-related AEs. The safety population included all patients who had undergone random assignment and received at least one dose of any trial treatment. AE, adverse event; IRR, infusion-related reaction.
非 KM Figure
FIG 4.Patient-reported convenience of the subcutaneous injection and intravenous infusion. Item 6 of the modified TASQ asked, “How convenient is it for you to have your [IV infusion/SC injection]?” The modified TASQ was completed by patients after treatment administration in cycle-1 (baseline), cycle-3, and at EOT. EOT data could have been collected after administration of the last dose. a C1D2 for patients who received IV amivantamab because of split dosing. C, cycle; D, day; EOT, end of treatment; IV, intravenous; SC, subcutaneous; TASQ, Therapy Administration Satisfaction Questionnaire.
非 KM Figure
FIG A1.PALOMA-3 study design. a Cycle 1 for intravenous amivantamab-lazertinib: Days 1, 2 (Day 2 applies to intravenous split dose only), 8, 15, and 22; Cycle 1 for subcutaneous amivantamab-lazertinib: Days 1, 8, 15, and 22; after Cycle 1 for all: Days 1, 15 (28-day cycles). Subcutaneous amivantamab is coformulated with recombinant human hyaluronidase. b Assessed by using modified TASQ. AUC, area under the concentration-time curve; C trough , observed serum concentration of amivantamab at steady state; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion mutation; NSCLC, non–small cell lung cancer; R, random assignment; TASQ, Therapy Administration Satisfaction Questionnaire.
非 KM Figure
FIG A2.Time to amivantamab discontinuation. The dashed lines indicate the median time to amivantamab discontinuation in the two groups, and the tick marks indicate censoring of data.
非 KM Figure
FIG A3.(A) Observed concentration-time profiles, (B) C trough , and (C) AUC D1-D15 of amivantamab. To capture the peak concentration of intravenous amivantamab, two samples were analyzed soon after the end of infusion (at 10 minutes and 2 hours after intravenous infusion). The upper and lower end of the boxes indicate the 25th and 75th quartiles, respectively, the triangles indicate the means, the horizontal lines within the boxes indicate the medians, and the error bars indicate 95% CIs. AUC, area under the concentration-time curve; AUC D1-D15 , AUC between Cycle 2 Day 1 and Day 15; C, Cycle; C trough , observed serum concentration of amivantamab at steady state; D, Day.
非 KM Figure
FIG A4.Best percentage change from baseline in target lesions: (A) subcutaneous group and (B) intravenous group. Target lesions were measured as the sum of the longest diameters. The number of patients with measurable disease at baseline was 206 in the subcutaneous group and 212 in the intravenous group; 190 and 195 patients, respectively, had postbaseline tumor assessments. SoD, sum of diameters.
非 KM Figure
FIG A5.DoR: (A) among confirmed responders and (B) among all responders. The efficacy population included all patients who had undergone random assignment. Included in this analysis were the 55 (confirmed) and 62 (including unconfirmed) responders (of the 206 patients with measurable disease at baseline by RECIST, v1.1) in the subcutaneous group and the 57 (confirmed) and 69 (including unconfirmed) responders (of 212 patients) in the intravenous group, respectively. Tick marks indicate censoring of data. DoR, response duration; NE, not estimable.
非 KM Figure
FIG A6.Incidence of IRRs by treatment cycle. IRR was counted only once per time frame per patient, and the event experienced by the patient with the worst toxicity was used. AE, adverse event; IRR, infusion-related reaction.
非 KM Figure